What are the recommended diagnostic steps, surveillance schedule, and treatment options for managing von Hippel‑Lindau (VHL) disease?

Von Hippel-Lindau Disease: Diagnostic and Management Approach

VHL disease requires genetic confirmation when possible, lifelong multiorgan surveillance starting in infancy, and timely surgical intervention before tumors become symptomatic to prevent irreversible organ damage and reduce mortality. 1

Diagnosis

Genetic Testing Indications

• Offer genetic testing to all first-degree relatives of individuals with a confirmed pathogenic VHL variant, as this provides definitive diagnosis 1
• Test any child presenting with VHL-associated lesions: retinal angioma, CNS hemangioblastoma, clear-cell renal carcinoma, pheochromocytoma/paraganglioma, endolymphatic-sac tumor, epididymal/adnexal papillary cystadenoma, multiple pancreatic cysts or neuroendocrine tumors, or multiple renal cysts 1

Clinical Diagnosis Without Genetic Testing

Clinical diagnosis is acceptable when: 1

• Known family history of VHL plus one of: CNS/retinal hemangioblastoma, pheochromocytoma, or renal carcinoma
• Simplex case with either: two hemangioblastomas, two visceral tumors, or one hemangioblastoma plus one visceral tumor

Surveillance Protocol

Ophthalmologic Surveillance

• Begin retinal screening within the first year of life and continue lifelong 1
• Examine every 6–12 months until age 30, then at least annually thereafter 1
• Use ultra-widefield color fundus photography and fluorescein angiography to detect small retinal hemangioblastomas 1
• Lifetime risk is 25–60%, with earliest diagnosis at birth; children face severe retinal damage if detection is delayed 1
• Perform pre-conception screening and repeat every 6–12 months throughout pregnancy 1

Pheochromocytoma Surveillance

• Start annual plasma-free metanephrines or urine fractionated metanephrines at age 5 (some protocols recommend age 2 due to cases diagnosed as early as 2 years) 1
• Conduct annual abdominal ultrasound between ages 8–15 1
• From age 16 onward, alternate ultrasound and MRI annually 1
• Lifetime risk is 10–25% with mean age at diagnosis of 27 years 1

CNS Hemangioblastoma Surveillance

• Initiate annual brain and spine MRI between ages 8–14 and continue yearly thereafter—biennial imaging is insufficient 1
• Lifetime risk is 60–80%; youngest case at age 9, mean diagnostic age 30 years 1

Renal Surveillance

• Begin annual abdominal ultrasound or MRI at age 16 1
• Renal manifestations occur in 25–75% of individuals 1
• Renal cell carcinoma risk ranges from 17–70%; earliest diagnosis at age 13, mean age 44 years 1

Endolymphatic-Sac Tumor (ELST) Surveillance

• Perform audiologic evaluation every 2–3 years from ages 5–15 1
• Every 2 years from age 15 onward 1
• Lifetime risk is 10–15%, with youngest documented case at age 6 1

Pancreatic Surveillance

• Annual abdominal imaging (ultrasound or MRI) starting at age 16 1
• Pancreatic cysts and neuroendocrine tumors develop in 35–75% of patients 1
• Earliest cyst identified at age 5, earliest neuroendocrine tumor at age 16 1

Treatment Strategies

Surgical Management

• Resect VHL-related tumors when they become symptomatic or reach size thresholds that increase operative risk 1
• Early detection of CNS hemangioblastomas enables surgical excision with minimal surrounding tissue injury 1
• Treat extramacular/extrapapillary retinal hemangioblastomas promptly to prevent permanent vision loss 1

Medical Therapy

• Belzutifan (HIF-2α inhibitor) is FDA-approved for adult patients with VHL-associated RCC, CNS hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery 2, 3

Critical Pitfall to Avoid

Delaying surgery until severe symptoms develop is associated with higher rates of intra-operative hemorrhage (particularly for large CNS hemangioblastomas) and irreversible organ damage 1

Care Coordination

Multidisciplinary Approach

• Coordinate management within specialized multidisciplinary centers staffed by subspecialists experienced in VHL 1
• Designate a coordinating physician to oversee referrals and inter-team communication 1
• Multiple medical specialties participate in diagnosis and treatment given the multiorgan involvement 4

Prognosis and Epidemiology

• Lifetime penetrance approaches 100% by age 75; inheritance is autosomal dominant with approximately 80% inherited and 20% de novo 1
• Although most VHL-associated tumors are histologically benign, morbidity from mass effect and surgical complications can be substantial 1
• Comprehensive surveillance programs have demonstrably reduced mortality from RCC, pancreatic neuroendocrine tumors, and CNS hemangioblastomas by facilitating early detection and timely intervention 1
• Mean life expectancy for VHL mutation-carriers born in 2000 is estimated at 67 years for men and 60 years for women, representing significant improvement over historical median life expectancy of 49 years 5